China Scandal One Early Challenge For New GSK Chairman
This article was originally published in PharmAsia News
Philip Hampton likely will have to deal with the fallout from the Chinese bribery scandal, as well as a major restructuring of the previously announced asset swap with Novartis, and increasing generic competition to its leading products.
You may also be interested in...
Decline in Advair sales to cointinue for several years as the portfolio transitions to new products, which have faced reimbursement challenges.
With GLP-1 sales increasing by 31% in the third quarter, Novo Nordisk has raised its sales and operating profit outlooks for 2020 to 5-8% at CER, and has outlined promising R&D progress against atherosclerosis and obesity.
GlaxoSmithKline's executive team outlined the progress the company is making against COVID-19, lupus nephritis, ovarian cancer and multiple myeloma.